ClinicalTrials.gg
RecruitingNCT07494305Illuminate1Updated Jul 27, 2026

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

A Phase 2 interventional study of LB-102 and Placebo in Bipolar I Disorder, sponsored by LB Pharmaceuticals Inc.. Recruiting at 26 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by LB Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo). Treatment is for 6 weeks.

Read the detailed description

This is a Phase 2, randomized, double blind, placebo controlled, multicenter study designed to assess the efficacy and safety of LB 102 in the treatment of adult patients with major depressive episodes (MDEs) associated with Bipolar I Disorder. Eligible patients will be randomly assigned in a 1:1 ratio to receive LB-102 or placebo as oral administration once daily (QD) treatment for 6 weeks

02

Conditions studied

  • Bipolar I Disorder

Keywords

  • Bipolar
  • Major depression episode
03

In context

Lead sponsor

LB Pharmaceuticals Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign IRB approved ICF, Stable living environment
  • Diagnosis of Bipolar1 disorder defined by criteria in the DSM 5 and currently experiencing a MDE without psychotic or mixed features, and supported by the SCID 5 CT
  • Currently experiencing an MDE that began at least 4 weeks but no more than 18 months prior to randomization
  • Currently treated in an out-patient environment
  • MADRS 10 total score ≥24 at both Screening and Baseline with a difference of \<20% in scores between visits.
  • Clinical Global Impression Scale, Bipolar Version Severity of Illness scale (CGI BP S) depression score ≥4 at both Screening and Baseline.
  • YMRS total score ≤12 at both Screening and Baseline.
  • Good physical health
  • of ≥18 and ≤40 kg/m2.
  • Eligibility confirmed centrally for the severity, diagnosis, and treatment history by the SAFER interview.

Exclusion criteria

Exclusion Criteria:

  • Sexually active woman of and male who are not practicing 2 different methods of or woman who is currently breast feeding
  • History of non-response to 2 adequate medication trials for depressive symptoms
  • Improvement of ≥20% in MADRS 10 total score between the screening and baseline assessments
  • Have bipolar disorder with mixed features or considered as rapid cyclers
  • Plan to initiate formal cognitive or behavioral therapy, systematic psychotherapy during the study, or plan to initiate such therapy during the study
  • History of disorders other than bipolar disorder, confirmed by previous psychiatric evaluation or the DSM 5 within 12 months prior to Screening
  • Experience of hallucinations, delusions, or any other psychotic symptomatology in the current MDE attributable to a primary DSM 5 diagnosis other than bipolar disorder.
  • Hospitalized for mania associated with Bipolar I Disorder within 30 days prior to Screening. Any previous manic phase must have completely resolved before enrollment in the study.
  • Significant risk for suicidal behavior during the study as determined by the Investigator's clinical assessment
  • Hypo or hyperthyroidism
  • Insulin dependent diabetes
  • Uncontrolled hypertension
  • Known significant cardiac disease
  • Laboratory results outside the defined protocol ranges
  • abnormal findings
  • Received electroconvulsive therapy (ECT) within 90 days prior to Screening.
  • Received Transcranial Magnetic Stimulation within 90 days prior to Screening
  • Currently taking prohibited medications as defined in the protocol
  • History of non-response and/or responded only to ketamine, ECT or vagus nerve stimulation
  • Received GLP-1 within 30 of screening
  • History of organ disease that in the opinion of the PI would not make the patient eligible for participation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
320 participants (estimated)

Study arms

  • Active comparator
    LB-102

    Patients will be randomized 1:1 to either active drug (LB-102) or Placebo. Dosing of LB-102 will start at 25 mg QD fixed dose for the first 3 weeks. At the start of Week 4, the dose of LB-102 may be increased to 50 mg QD based on the Clinical Global Impression Scale, Bipolar Version (CGI BP) improvement score.

    Drug: LB-102

  • Placebo comparator
    Placebo

    Patients will be randomized 1:1 to either LB-102 or placebo. Those patients on placebo will take one table QD for the length (6 weeks) of the clinical study. Patients will receive a new bottle of medication each week. Patients and PI, study staff will be blinded to which treatment (LB-102 or placebo), patients are randomized to. Patients will restart antidepressant or mood stabilizer treatment (if applicable) after the last dose of the study treatment on study day 43

    Other: Placebo

Interventions

  • DrugLB-102

    N-methyl amisulpride

  • OtherPlacebo

    Inactive substance that looks identical to the active treatment

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery Åsberg Depression Rating -10 core symptom scale (MADRS-10)

    The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

    Time frame: Baseline to Day 42

Secondary outcomes

  1. Incidence of Adverse Events

    Adverse Events (AEs) will be characterized by type, severity, seriousness, and relationship to treatment. All AEs will be coded using the most up-to-date version of the Medical Dictionary for Regulatory Activities (MedDRA). The incidence of AE is the number and percentage of patients reporting the event at least once during the study, and will be counted only once per system organ class (SOC) and preferred term (PT).

    Time frame: Baseline to Day 56

  2. Incidence of Treatment-emergent Mania based on the Young Mania Rating Scale (YMRS) Total Score

    The Young Mania Rating Scale is a clinical assessment utilized to assess manic symptoms and their severity. The YMRS consists of 11 items, each focusing on a different aspect of mania. The total score can range from 0 to 60 with higher scores indicating more severe manic symptoms.

    Time frame: Baseline Day 42

07

Study locations

26 of 26 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Feb 2028, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2025
First posted
Mar 27, 2026
StartActual
Jan 23, 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07494305
Lead sponsor
LB Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Jan 23, 2026
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Jul 27, 2026

Study contacts

George Nomikos
Contact
clinicaltrials@lbpharma.us
(212) 605-0300

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LB-102

Start the discussion